Full remission after failure on platinum-based chemotherapy, autologous stem cell transplant, and a number of ICIs (anti–PD-1, anti–CTLA-4, and anti–TIGIT)
The publication, titled “Salvage remedy with allogeneic invariant pure killer T cells in a closely pre-treated germ cell tumor,” presents a affected person case from MiNK’s scientific trial (NCT05108623). The affected person had progressed after a number of strains of remedy—together with platinum-based chemotherapy, autologous stem cell transplant, and a number of immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT)—and obtained a single infusion of agenT-797 alongside nivolumab. The affected person achieved a whole scientific, radiologic, and biochemical remission, with no proof of illness over two years later. Donor iNKT cells had been detectable as much as six months post-infusion, and therapy was well-tolerated with no cytokine launch syndrome (CRS) or graft-versus-host illness (GVHD).
“This case exemplifies the highly effective potential of iNKT cells in treating even essentially the most difficult cancers,” mentioned Dr. Benjamin Garmezy, Assistant Director of Genitourinary Analysis for Sarah Cannon Analysis Institute at SCRI Oncology Companions. “We noticed a outstanding response in a affected person who had exhausted normal and experimental therapies, providing compelling proof to additional pursue scientific research of iNKT cell therapies in stable tumors.”
Sturdy Responses & Immune Activation in Stable Tumors with Allo-iNKT Remedy
These findings are a part of a rising physique of scientific proof supporting the potential of agenT-797 in stable tumors. On the 2025 inaugural AACR Immuno-Oncology assembly, MiNK introduced knowledge from its Part 2 trial in 2L gastric most cancers, demonstrating immune activation, elevated tumor infiltration, and early indicators of tumor management in sufferers beforehand refractory to checkpoint inhibitors. Notably, prolonged survival past 12 months was noticed in a number of sufferers—an final result hardly ever seen on this setting. These scientific observations had been additional bolstered in a separate peer-reviewed case report revealed in Oncogene, which described a affected person with metastatic gastric most cancers who achieved a 42% tumor discount and greater than 9 months of progression-free survival following a single infusion of agenT-797 together with nivolumab.
Collectively, these knowledge spotlight the potential of agenT-797 to reshape the tumor microenvironment and ship sturdy scientific exercise, even in closely pretreated, immunotherapy-resistant cancers. The continued Part 2 trial in gastric most cancers (NCT06251973) is actively enrolling, with further readouts anticipated in upcoming months. You possibly can entry the complete publication right here.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical firm advancing a brand new class of allogeneic invariant pure killer T (iNKT) cell therapies and precision-targeted immune applied sciences. MiNK’s proprietary platform is designed to revive immune steadiness and drive cytotoxic responses throughout most cancers, immune-mediated ailments, and pulmonary immune failure. The corporate’s lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell remedy at present in scientific improvement for graft-versus-host illness (GvHD), stable tumors, and extreme pulmonary irritation. MiNK can also be advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery instruments that allow extremely particular immune focusing on throughout tumor and tissue sorts. With a scalable manufacturing course of and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is dedicated to delivering accessible, sturdy, and broadly relevant immune reconstitution therapies. For extra info, go to www.minktherapeutics.com or observe us on X @MiNK_iNKT. Info essential to traders is routinely posted to our web site and social media channels.
About AgenT-797
AgenT-797 is an allogeneic invariant pure killer T (iNKT) cell remedy that harnesses the twin energy of innate and adaptive immunity. iNKTs perform as “grasp regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and reminiscence. This distinctive biology permits a sturdy, pathogen-agnostic immune response that may be directed in opposition to hard-to-treat tumors.
Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to offer accessible, transformative therapy choices. In scientific trials, agenT-797 can bolster peripheral reminiscence T-cell activation, improve tumor infiltration, and probably enhance outcomes for sufferers with stable cancers (Cytryn et al., AACR IO 2024;Oncogene, 2024), in addition to cut back irritation in critically ailing sufferers with extreme respiratory pathology (Nature Communications, 2024).
Ahead Trying Statements
This press launch comprises forward-looking statements which might be made pursuant to the secure harbor provisions of the federal securities legal guidelines, together with statements concerning the therapeutic potential, anticipated profit, plans and timelines of iNKT cells. These forward-looking statements are topic to dangers and uncertainties that would trigger precise outcomes to vary materially. These forward-looking statements are topic to dangers and uncertainties, together with the components described beneath the Danger Elements part of the newest Kind 10-Ok, Kind 10-Q and the S-1 Registration Assertion filed with the SEC. MiNK cautions traders to not place appreciable reliance on the forward-looking statements contained on this launch. These statements communicate solely as of the date of this press launch, and MiNK and Agenus with no obligation to replace or revise the statements, apart from to the extent required by legislation. All forward-looking statements are expressly certified of their entirety by this cautionary assertion.
CONTACT: Investor Contact 917-362-1370 investor@minktherapeutics.com Media Contact 781-674-4428 communications@minktherapeutics.com
